·Clinical Research·

# QT interval dispersion in the patients with central serous chorioretinopathy

Necati Dagli<sup>1</sup>, Burak Turgut<sup>2</sup>, Rumeysa Tanyildizi<sup>3</sup>, Sabiha Kobat<sup>2</sup>, Mehmet Ali Kobat<sup>3</sup>, Orhan Dogdu<sup>1</sup>

<sup>1</sup>Department of Cardiology, School of Medicine, Firat University, Elazig 23119, Turkey

<sup>2</sup>Department of Ophthalmology, School of Medicine, Firat University, Elazig 23119, Turkey

<sup>3</sup>Elazig Education and Research Hospital, Elazig 23200, Turkey

**Correspondence to:** Burak Turgut. Department of Ophthalmology, Firat University School of Medicine, Elazig 23119, Turkey. drburakturgut@gmail.com.

Received: 2014-01-22 Accepted: 2014-06-12

# Abstract

• AIM: To evaluate QT dispersion (QTD) in patients with central serous chorioretinopathy (CSC).

• METHODS: This clinical, comperative, case -control study included 30 patients with CSC at acute phase (Group 1) and 30 age- and sex-matched healthy subjects (Group 2, the control group). From all subjects, a 12-lead surface electrocardiography was obtained. The heart rate (HR), QT maximum (QT<sub>max</sub>), QT minimum (QT<sub>min</sub>), QT corrected (QT<sub>c</sub>), QTD and T<sub>mean</sub> were manually measured and analyzed. Student's *t*-test and Pearson's method of correlation were used for statistical analysis.

• RESULTS: The patient and control groups were matched for age, smoking status (rate and duration) and gender. There were no significant differences with regard to these among the groups (P>0.05). The participants included 19 men (63.3%) and 11 women (36.7%) in Group 1, 20 men (66.7%) and 10 women (33.3%) in Group 2.

QT<sub>max</sub>, QTD and QT<sub>c</sub> were significantly higher than those of healthy controls (P<0.001 for QT<sub>max</sub>, P=0.01 for QTD and P=0.001 for QT<sub>c</sub>). QT<sub>min</sub>, T<sub>mean</sub> and HR did not differ significantly between the study groups (P=0.28 for QT<sub>min</sub>, P=0.56 for T<sub>mean</sub> and P>0.05 for HR). No significant correlation was found between duration of the disorder and QTD values (r=0.13, P>0.05).

• CONCLUSION: These findings suggest that CSC may be associated with an increase in QTD and that the patients might be at risk for ventricular arrhythmia.

• **KEYWORDS:** central serous chorioretinopathy; electrocardiography; QT dispersion; ventricular arrhythmia **DOI:10.3980/j.issn.2222–3959.2015.01.11**  Dagli N, Turgut B, Tanyildizi R, Kobat S, Kobat MA, Dogdu O. QT interval dispersion in the patients with central serous chorioretinopathy. *Int J Ophthalmol* 2015;8(1):61–65

## INTRODUCTION

r entral serous chorioretinopathy (CSC) is characterized U by serous detachment of the neurosensorial retina and/or the retinal pigment epithelium (RPE) frequently in the macular region <sup>[1]</sup>. Spontaneous resolution of serous retinal detachment is common in acute CSC with RPE changes while recurrent or chronic detachment is often associated with diffuse retina pigment epitheliopathy, which is resulting in the RPE atrophy and secondary subretinal neovascularization or polypoidal choroidal vasculopathy. Subsequently, CSC may cause persistent visual impairment<sup>[2]</sup>. Although the pathogenesis of CSC is unknown, it has been considered that the CSC may be due to focal RPE defect or choroidal lobular ischemia and choroidal venous congestion <sup>[3-5]</sup>. Recent studies have shown the association of CSC with psychological stress; type A personality; glucocorticoid treatment; endogenous hypercortisolism like Cushing's syndrome; systemic hypertension; and pregnancy. Thus, the increased levels of serum catecholamine, or glucocorticoid, or both, have been thought to play a role in the pathogenesis of CSC, in all these conditions<sup>[1, 6-8]</sup>.

Recent studies showed that the protection against sudden death by use of beta-adrenergic antagonists and left upper thoracic sympathectomy confirmed the importance of sympathetic stimulation as a trigger of arrhythmias <sup>[9,10]</sup>. It has been known that adrenergic antagonists have been also used in the treatment of CSC. Thus, catecholamines play an important role at the development in both CSC and arrhythmia and could exaggerate the preexisting cardiac ritm abnormalities. Although, there is no data in literature, it is possible that CSC is associated with cardiac arrhythmias because of above mentioned tight relation with sympathetic stimulation.

Cardiac arrhythmia such as ventricular fibrillation is one of most important causes of sudden death. Interlead variability of the QT interval (QT dispersion, QTD) detected in standard electrocardiography (ECG) has been proposed as a marker of electrical instability of the heart <sup>[11,12]</sup>. QTD is defined as the

difference between the longest and shortest QT interval measured in a 12-lead of the surface ECG. QT interval is the time period from the beginning of the Q wave to the return of the T wave to the isoelectric line in an ECG. QTD is markedly increased in patients with long QT Syndrome (LQTS), which has been considered to indicate arrhythmia risk <sup>[13]</sup> in this disease. Sympathetic nervous stimulation and catecholamines are known to produce QT prolongation and ventricular arrhythmias in familial LQTS<sup>[14,15]</sup>.

QTD reflects regional heterogeneity of ventricular myocardial repolarization. It has been suggested that QTD could be an important indicator of the risk of ventricular arrhythmia<sup>[16]</sup>. A higher QTD means a higher heterogeneity in ventricular repolarization and the higher the ventricular instability<sup>[17]</sup>. This may lead to serious ventricular arrhythmias and, consequently sudden cardiac death<sup>[18]</sup>. To the best of our knowledge, no previous studies have examined the possible relation between QT elongation and CSC. In our study, we aimed to research the possible relation between CSC and cardiac arrhytmia by evaluating the "QT" segments in standard ECG.

## SUBJECTS AND METHODS

Subjects This study included 30 patients with active CSC (Group 1), and 30 age- and sex-matched healthy subjects (Group 2). The study was designed as a clinical comperative case-control study and according to Helsinki Declaration and approved by the institutional ethics committee. Informed consents were obtained from the patients and the volunteers. Methods

Inclusion criteria All participants were free of all medications (also including vasoactive or psychotropic agents) at least in the previous two weeks.

Group 1 included the patients with acute CSC characterized by detachment of the neurosensorial retina caused by accumulation of serous fluid between the photoreceptor outer segments and the RPE in combination with monofocal or multifocal changes in the RPE documented by fundus fluorescein angiography (FFA) and optical coherence tomography (OCT).

The time from the beginning of visual complaints of patients until admitting to our clinic was accepted as the disease duration. A typical acute CSC is characterized with continuation of complaints and/or serous retinal detachment less than 6mo<sup>[19]</sup>.

Group 2 (control group) included same number of healthy subjects (10 females and 20 males; age  $42.3 \pm 8.9$ y) by matched sex, age, and smoking without exclusion criteria.

Exclusion criteria Patients at inactive, recurrent or chronic phases of disease were not included in the study.

Participants having current or previous a severe cardiac (congestive heart failure, myocardial infarction, disease

coronary artery stenosis, cardiomyopathy, valvular heart disease, a pacemaker), hypertension, existence of low ejection fraction and a severe systemic illness (chronic obstructive pulmonary disease, diabetes mellitus, cancer, etc.) that could influence autonomic functioning were also excluded from study.

Patients with history of previous coronary vascular surgery or intervention and any intraocular surgery, laser photocoagulation or intravitreal injection for CSC were also excluded.

Electrocardiographic recordings, measurements and analysis The electrocardiographic recordings were carried out in the same quiet room during spontaneous breathing, following 10min of adjustment in the supine position in morning hours. From all subjects, a 12-lead surface ECG was obtained. During recordings, participants were not allowed to speak. The ECGs were recorded at a paper at 10 mm/mV amplitude and 25 mm/s rate speed. Three leads were recorded simultaneously. To improve accuracy, all measurements were performed with calipers and magnifying lens for defining the ECG deflection, and the heart rate (HR), QT maximum  $(QT_{max})$ , QT minimum  $(QT_{min})$ , QT corrected  $(QT_c)$ , QTD and  $T_{mean}$  were manually measured and analyzed by an investigator blinded to the clinical data <sup>[20]</sup>. These recordings were also analyzed by another investigator to determine the interinvestigator variability.

The QT interval was manually measured by using hand-held calipers from the beginning of the QRS complex to the end of the T-wave in all 12 leads. The end of the T-wave was described as the intersection between a tangent to the terminal slope of the T-wave and the PR baseline. Only monophasic well defined T-waves were accepted for measurement. If the end of the T-wave could not be identified because of the low amplitude of the T-wave, then the lead was excluded from analysis. If a U-wave was present, then a tangential line was drawn on the terminal slope of the T-wave and the end of the T-wave was determined as the point of intersection of this line with the isoelectric base. The QT interval and the preceding RR interval were measured in three consecutive cycles. In each lead mean of the corrected QT<sub>c</sub> interval of three consecutive beats was considered as the QT<sub>c</sub> interval of that lead<sup>[20-22]</sup>.

The heart rate-corrected QT interval [QT<sub>c</sub>, millisecond (ms)] was calculated by using Bazett's formula  $[QT_c=QT/\sqrt{(RR)}]$ for each derivation. The  $QT_{c}$  (ms) was defined as the absolute difference between the maximum  $(QT_{cmax})$  and minimum (QT<sub>cmin</sub>) QT<sub>c</sub> interval in any of the ECG leads<sup>[23]</sup>. To determine the intraobserver variability of QT<sub>c</sub> interval measurements, 20 randomly selected electrocardiograms were analyzed by the same observer at a different time. These recordings were also analyzed by another observer to determine the interobserver variability.

**Statistical Analysis** Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS) version 11.0 (SPSS Inc., Chicago, IL, USA). In the statistical analysis, Student's t-test and Pearson's method of correlation were used. In addition, analysis covariance (ANCOVA) was used, with HR as covariate. All data are presented as mean $\pm$  standard deviation (SD). A P value less 0.05 was considered as significantly.

# RESULTS

Thirty healthy subjects (Group 1) and 30 patients with acute CSC (Group 2) were enrolled in this study. The participants included 19 men (63.3%) and 11 women (36.7%) in Group 1, 20 men (66.7%) and 10 women (33.3%) men in Group 2. The mean ages of the Group 1 and Group 2 were  $42.0\pm6.2$  and  $42.3\pm8.9$ y, respectively. The study groups were matched for age, smoking status (rate and duration) and sex and there were no significant differences with regard to these among the groups (P > 0.05). Demographic data of participants in the study groups are demonstrated in Table 1. The mean duration of disease for the patient group was  $24.7 \pm 8.3$ d. Demographic data of participants in the study groups are summarized in Table 1.

The electrocardiographic data are summarized in Table 1.  $QT_{maxs}$ , QTD and  $QT_c$  were significantly higher than those of healthy controls (P < 0.001 for  $QT_{maxs}$ , P = 0.01 for QTD and P = 0.001 for  $QT_c$ ).  $QT_{min}$  and  $T_{mean}$  were not showed significantly statistical difference in the patients group than in the controls (P=0.28 for  $QT_{min}$  and P=0.56 for  $T_{mean}$ ). Heart rate did not differ significantly between the groups (P>0.05). No significant correlation was found between duration of the disorder and QTD values (r=0.13, P>0.05, Figure 1). The interobserver variability was less than 5% for all of the electrocardiographic variables.

# DISCUSSION

Although there are various risk factors for the development of CSC, psychosomatic factors and the increased levels of serum catecholamine or both have been thought to have important role in the pathogenesis of CSC. Yannuzzi <sup>[1]</sup> considered that type A personality might be strongly associated with the sympathetic release in CSC and that macula was the target tissue for this pathology.

In the previous studies, it has been suggested that CSC could be created by intravenous epinephrine in the experimental monkey model <sup>[24-27]</sup>. It was postulated that elevated catecholamine levels in patients with CSC might cause choroidal vasoconstriction by activating the sympathetic nervous system. It was considered that the elevation of choroidal hydrostatic pressure caused by choroidal vasoconstriction leads to the breakdown of tight junctions among RPE cells, allowing fluid to pass from the choroid to the subretinal space <sup>[28]</sup>. Previous studies have also demonstrated that CSC patients have some traits such as a




Figure 1 Data of correlation between duration of disorder and QTD values.

Table 1 Demographical data and QT segment measurements of the study groups

Demographical and electrocardiographical data	Patients	Controls	Р
Mean age (a±SD)	42.0±6.2	42.3±8.9	0.91
Sex ratio (F/M)	19/11	20/10	0.82
Duration of disease (d)	$24.7 \pm 8.3$	-	-
QT max	434.5±12.5	416.1±11.8	< 0.001
QT min	373.1±21.9	366.7±18.4	0.28
QTD	61.3±13.7	49.4±16.5	0.01
QT <sub>c</sub>	482.1±17.5	466.1±15.3	0.001
T <sub>mean</sub>	$1.62 \pm 0.2$	$1.65 \pm 0.02$	0.56
Heart rate (beats/min)	70.9±12.5	71.5±10.9	0.87

neuroticism, emotional instability, introversion and alexithymia, as well as type A behavior. All these personality traits point to emotional disregulation <sup>[29-33]</sup>. Psychological stress or disorders associated with increased sympathetic nervous system stimulation contribute to the development of CSC as an important risk factor<sup>[34-36]</sup>.

In some studies on QTD in some physiciatric diseases including panic disorder, social fobia and anorexia nervosa, it was considered that QTD might be associated with these disorders <sup>[37-39]</sup>. Recent clinical studies also demonstrated that the prognostic significance of the QT interval and QTD in the patients with type I DM, carbon monooxyde poisoning, ankylosing spondylitis, electrolyte imbalance, undergoing dialysis, renal transplant and severe burns<sup>[40-45]</sup>.

In many clinical studies on cardiologic patients, it was reported that QTD was a risk factor for arrhythmia and unexpected cardiac death patients with LQTS and chronic heart failure, respectively <sup>[12,46,47]</sup>. It has been well known that sympathetic nervous stimulation and catecholamines caused QT prolongation and ventricular arrhythmias in familial LQTS<sup>[14,15]</sup>.

QT dispersion reflects regional heterogeneity of ventricular myocardial repolarization and has been suggested as an important indicator of the risk of arrhythmia, in addition to

# QT interval dispersion and central serous chorioretinopathy

the QT interval. QT interval refers to the overall duration of the electrical activation and resting of the ventricle, corresponding to the location of each lead, and is inversely correlated with the HR <sup>[16]</sup>. Normally, QTD is within 40-60ms; if it exceeds 100ms or rises by 100% from baseline, the condition is considered to be pathologic. A higher QTD means a higher heterogeneity in ventricular repolarization and the higher the ventricular instability<sup>[17]</sup>. Nonhomogeneous conduction velocity in different regions of ventricles, *i.e.* increase in QTD, may lead to serious ventricular arrhythmias and, consequently sudden cardiac death<sup>[18, 46, 47]</sup>.

To our best knowledge, this is the first study which investigated QTD in patients with CSC. In our study, we found that QTD in the patients with CSC were significantly higher than those of healthy controls. Thus, we suggest that QTD may be a marker of CSC and that otherwise; the patients with CSC might be at risk for ventricular arryhthmia and sudden death. However, further studies having large sample number and with long follow-up time, in which QTD values are screened at different phases such as inactive, chronic, recurrent throughout the course of the disorder, are needed to support our opinion.

Our study has some limitations: electrocardiographical measurements were performed using a  $10 \times \text{lens}$ , not using computer programming or automated measurement methods. Electrophysiological evaluation was not performed. The patients were not followed up longitudinally for morbidity and mortality. Finally, in our study, catecholamines, which might associate with CSC, were not evaluated. However, this assessment is difficult because the levels of these hormones may be easily affected by various factors and situations.

In conclusion, QTD detected by ECG, an easily applied non-invasive method may show the risk of ventricular arrhythmia in the patients with CSC. As QTD may be associated with CSC, and the patients with CSC should be closely followed-up because they might be at risk cardiac ventricular arrythmia.

### ACKNOWLEDGEMENTS

Conflicts of Interest: Dagli N, None; Turgut B, None; Tanyildizi R, None; Kobat S, None; Kobat MA, None; Dogdu O, None.

#### REFERENCES

1 Yannuzzi LA. Type A behavior and central serous chorioretinopathy. *Retina* 2012;32(Suppl 1):709

2 Ross A, Ross AH, Mohamed Q. Review and update of central serous chorioretinopathy. *Curr Opin Ophthalmol* 2011;22(3):166-173

3 Quin G, Liew G, Ho IV, Gillies M, Fraser-Bell S. Diagnosis and interventions for central serous chorioretinopathy: review and update. *Clin Experiment Ophthalmol* 2013;41(2):187-200

4 Prunte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. *Am J Ophthalmol* 1996;121(1):26-34

5 Scheider A, Naseman JE, Lund OE. Fluorescein and indocyanine gren angiographies of central serous choriodopathy by scanning laser ophthalmoscopy. Am J Ophthalmol 1993;115(1):50-56

6 Haimovici R, Rumelt S, Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy. *Ophthalmology* 2003;110 (4): 698-703

7 Eckstein MB, Spalton DJ, Holder G. Visual loss from central serous retinopathy in systemic lupus erythematosus. *Br J Ophthalmol* 1993;77(9): 607-609

8 Bouzas EA, Karadimas P, Pournaras CJ. Central serous chorioretinopathy and glucocorticoids. *Surv Ophthalmol* 2002;47(5):431-448

9 Moss AJ, Schwartz PJ, Crampton RS, Tzivoni D, Locati EH, MacCluer J, Hall WJ, Weitkamp L, Vincent GM, Garson A Jr, et al. The long QT syndrome: prospective longitudinal study on 382 families. *Circulation* 1991;84(3):1136-1144

10 Wang L, Feng G. Left cardiac sympathetic denervation as the first-line therapy for congenital long QT syndrome. *Med Hypotheses* 2004;63 (3): 438-441

11 Hii JT, Wyse G, Gillis AM, Duff HJ, Solylo MA, Mitchell LB. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone. *Circulation* 1992;86(5): 1376–1382

12 Day CP, McComb JM, Campbell RW. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. *Br Heart J* 1990;63(6): 342-344

13 De Ambrioggi L, Negroni MS, Monza E, Bertoni T, Schwartz PJ. Dispersion of ventricular repolarization in the long QT syndrome. *Am J Carchio*/1991; 68(6): 614-620

14 Schwartz PJ. Idiopathic long QT syndrome: progress and questions. *Am Heart* J 1985;109(2):399-411

15 Shimizu W, Ohe T, Kurita T, Takaki H, Aihara N, Kamakura S, Matsuhisa M, Shimomura K. Early after depolarizations induced by isoproterenol in patients with congenital long QT syndrome. *Circulation* 1991;84(5):1915–1923

16 Hantukova K, Malik M, Yi G, Camm AJ. Adjustment of QT dispersion assessed from 12 lead ECG's for different number of analysed electrocardiographic leads: comparison of stability of diff erent methods. *Br Heart*, J 1994;72(4): 390–396

17 van de Loo A, Arendts W, Hohnloser SH. Variability of QT dispersion measurements in the surface electrocardiogram in patients with acute myocardial infarction and in normal subjects. *Am J Cardiol* 1994;74(11): 1113–1118

18 Pye MP, Cobbe SM. Mechanisms of ventricular arrhythmias in cardiac failure and hypertrophy. *Cardiovasc Res* 1992;26(8):740-750

 Bujarborua D. Long term follow-up ofidiopathic central serous chorioretinopathy without laser. *Acta Opthalmol Scand* 2001;79(4):417-421
 Üçkuyu A, Ceylan Çiftçi F, Çiftçi Ö, Özçimen EE, Toprak E, Turhan E. Effect of ovulation induction on QT dispersion in electrocardiography. *Turk J Med Sci* 2012; 42(3): 491-496

21 Elming H, Holm E, Jun L, Torp-Pedersen C, Køber L, Kircshoff M, Malik M, Camm J. The prognostic value of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Danish citizens. *Eur Heart J* 1998;19(9):1391–1400

22 Minoretti P, Politi P, Martinelli V, Emanuele E, Bertona M, Falcone C, Geroldi D. QT interval duration in apparently healthy men is associated with depression-related personality trait neuroticism. *J Psychosom Rcs* 2006;61(1):19-23

23 Luo S, Michler K, Johnston P, Macfarlane PW. A comparison of commonly used QT correction formulae: the effect of heart rate on the QTc of normal ECGs. *J Electrocardiol* 2004;37 Suppl:81–90

24 Nicholson B, Noble J, Forooghian F, Meyerle C. Central serous chorioretinopathy: update on pathophysiology and treatment. *Surv Ophthalmol* 2013;58(2):103-126

25 Yoshioka H, Katsume Y, Akune H. Experimental central serous chorioretinopathy in monkey eyes: fluorescein angiographic findings. *Ophthalmologica* 1982;185(3):168–178

26 Yoshioka H, Katsume Y, Akune H. Studies on experimental central serous chorioretinopathy. Fluorescein angiography and histopathology during the course of spontaneous remission. *Nihon Ganka Gakkai Zasshi*. 1984;88(5):819–828

27 Jampol LM, Weinreb R, Yannuzi L. Involvement of corticosteroids and catecholamines in the pathogenesis of central serous chorioretinopathy: a rationale for new treatment strategies. *Ophthalmology* 2002;109 (10): 1765–1766

28 Pryds A, Sander B, Larsen M. Characterization of subretinal fluid leakage in central serous chorioretinopathy. *Invest Ophthalmol Vis Sci* 2010;51(11):5853-5857

29 Lipowski ZJ, Kiriakos RZ. Psychosomatic aspects of central serous retinopathy: a review and case report. *Psychosomatics* 1971;12(6):398-401
30 Lazarus RS. *Emotion and Adaptation*. London: Oxford University Press; 1991

31 Werry H, Arends C. Investigation in patients with central serous retinopathy with the MMPI Saarbrücken (author's transl). *Klin Monatshl Augenheilkd* 1978;172(3):363-370

32 Spahn C, Wiek J, Burger T, Hansen L. Psychosomatic aspects in patients with central serous chorioretinopathy. *Br J Ophthalmol* 2003;87 (6):704-708

33 Conrad R, Bodeewes I, Schilling G, Geiser F, Imbierowicz K, Liedtke R. Central serous chorioretinopathy and psychological stress. *Ophthalmologe* 2000; 97(8):527–531

34 Conrad R, Weber NF, Lehnert M, Holz FG, Liedtke R, Eter N. Alexithymia and emotional distress in patients with central serous chorioretinopathy. *Psychosomatic* 2007;48(6):489-495

35 Tittl MK, Spaide RF, Wong D, Pilotto E, Yannuzzi LA, Fisher YL, Freund B, Guyer DR, Slakter JS, Sorenson JA. Systemic findings associated with central serous chorioretinopathy. *Am J Ophthalmol* 1999;128 (1): 63–68

36 Friedman BH, Thayer JF. Anxiety and autonomic flexibility: a

cardiovascular approach. Biol Psychol 1998;47(3):243-263

37 Atmaca M, Yavuzkir M, Izci F, Gurok MG, Adiyaman S. QT wave dispersion in patients with panic disorder. *Neurosci Bull* 2012;28 (3): 247-252

38 Nahshoni E, Gur S, Marom S, Levin JB, Weizman A, Hermesh H. QT dispersion in patients with social phobia. *J Affect Disord* 2004;78(1):21–26 39 Nahshoni E, Weizman A, Yaroslavsky A, Toledano A, Sulkes J, Stein D. Alterations in QT dispersion in the surface electrocardiogram of female adolescents diagnosed with restricting-type anorexia nervosa. *J Psychosom Res* 2007;62:469–472

40 Zdarska D, Peliskova P, Charvat J, Slavícek J, Mlcek M, Medová E, Kittnar O. ECG body surface mapping (BSM) in type 1 diabetic patient. *Physiol Res*2007; 56(4): 403-410

41 Yelken B, Tanriverdi B, Cetinbas F, Memis D, Süt N. The assessment of QT intervals in acute carbon monoxide poisoning. *Anadolu Kardiyol Derg* 2009;9(5):397-400

42 Yildirir A, Aksoyek S, Calguneri M, Aytemir K, Kabakci G, Ovunc K, Nazli N, Ozmen F, Oto A, Kes S. QT dispersion as a predictor of arrhythmic events in patients with ankylosing spondylitis. *Rheumatology (Oxford)* 2000;39(8):875–879

43 Shugushev KhKh, Shugushev ZKh, Khamizova MM, Vasilenko VM. Effect of programmed hemodialysis on parameters of ventricular repolarization and cardiac rhythm disturbances in patients with terminal renal failure. *Kardiologiia* 2004;44(5):67–70

44 Monfared A, Ghods AJ. Improvement of maximum corrected QT and corrected QT dispersion in electrocardiography after kidney transplantation. *Iran J Kidney Dis* 2008;2(2):95–98

45 Osada M, Tanaka Y, Komai T, Maeda Y, Kohno I, Umetani K, Sawanobori T, Ijiri H, Komori S, Tamura K. QT dispersion in patients with severe burns in intensive care unit. *Intensive Care Med* 2000;26(10):1581 46 Barr CS, Naas A, Freeman M, Struthers AD. QT dispersion and sudden unexpected death in chronic heart failure. *Laucet* 1994;343 (8893): 327–329

47 Manttari M, Oikarinen L, Manninen V, Viitasalo M. QT dispersion as a risk factor for sudden cardiac death and fatal myocardial infarction in a coronary risk population. *Heart* 1997;78(3):268-272